PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00623740
First received: February 7, 2008
Last updated: September 17, 2013
Last verified: September 2013

February 7, 2008
September 17, 2013
April 2008
January 2016   (final data collection date for primary outcome measure)
dichotomous variable: survival without BPD at 36 weeks PMA. [ Time Frame: add 8 to12 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00623740 on ClinicalTrials.gov Archive Site
  • features of WMI on MRI performed between 36-40 weeks PMA [ Time Frame: 8-12 weeks ] [ Designated as safety issue: No ]
  • neurodevelopmental outcome [ Time Frame: 18 month-3 years ] [ Designated as safety issue: Yes ]
  • Death before discharge [ Time Frame: discharge ] [ Designated as safety issue: No ]
  • BPD 28 days and 36 weeks [ Time Frame: 28 days and 36 weeks ] [ Designated as safety issue: No ]
  • duration of mechanical ventilation and O2 supplementation [ Time Frame: inclusion to discharge ] [ Designated as safety issue: No ]
  • need for vasopressors [ Time Frame: inclusion to discharge ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates
Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial

There is increasing evidence linking a fetal and early neonatal systemic inflammatory response syndrome to the subsequent development of bronchopulmonary dysplasia (BPD) and white matter injury (WMI) in very preterm infants. Babies with evidence of adrenal insufficiency early in life may not be able to control the inflammatory response and are thereby more likely to develop BPD than babies who do not show such evidence of inflammation. We designed a randomized controlled trial to test the hypothesis whether very preterm babies at high-risk of BPD, treated with low doses of HC during the first 10 days of life, are more likely to survive without BPD at 36 weeks of post-menstrual age (PMA), compared to babies treated with placebo.

Individual patients and study procedures. Entry criteria: gestational age between 24 weeks and 27 weeks + 6 days, babies born to mother with either clinical chorioamnionitis, preterm and prelabor rupture of the membranes (PPROM), or preterm labor, written informed consent obtained before inclusion and randomization. Exclusion criteria: babies born with birth weight below the 3th percentile, PPROM before 22 weeks, major fetal anomaly or congenital malformation, mother refusal or inability to provide consent. Stratification: stratum A: 24-25 weeks and stratum B: 26-27 weeks. Centrally controlled randomization takes place between 12 and 48 hours of age and patients assigned to the HC group are treated with 0,5 mg/kg HC intravenously twice a day for seven days and once a day for the next three days. Ibuprofen is only given to babies with persistent ductus arteriosis (PDA) echocardiographically confirmed at 24 hours of age or older.

Outcome variables. The primary outcome is a dichotomous variable: survival without BPD at 36 weeks PMA. A consistent physiologic definition of BPD will be used by all participating centres (Walsh MC, Pediatrics 2004;114:1305-11). Secondary outcome variables include features of WMI on MRI performed at 40 weeks PMA and neurodevelopmental outcome at 2-year of corrected age. Other outcome variables include death before discharge, BPD at 28 days and 36 weeks, duration of mechanical ventilation and O2 supplementation, need for vasopressors, use of open-labeled postnatal steroids (HC or dexamethasone), confirmed or suspected early and late onset sepsis, PDA, gastrointestinal perforation, NEC, ROP, IVH, biological markers of the neonatal inflammatory response syndrome.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Bronchopulmonary Dysplasia
  • Drug: hydrocortisone
    Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
    Other Name: hydrocortisone upjohn 100mg
  • Drug: placebo
    intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
  • Experimental: 1: hydrocortisone
    1: active arm treated with low doses of HC during the first 10 days of life
    Intervention: Drug: hydrocortisone
  • Placebo Comparator: 2: Placebo
    2:placebo arm treated with placebo at the same conditions than active arm
    Intervention: Drug: placebo
Baud O. [Postnatal steroid treatment in preterm infants: risk/benefit ratio] J Gynecol Obstet Biol Reprod (Paris). 2005 Feb;34(1 Suppl):S118-26. Review. French.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
786
January 2016
January 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Gestational age between 24 weeks and 27 weeks + 6 days
  • Babies born to mother with either clinical chorioamnionitis, preterm and prelabor rupture of the membranes (PPROM), or preterm labor
  • Written informed consent obtained before inclusion and randomization.

Exclusion Criteria:

  • Babies born to mothers with birth weight below the 3th percentile
  • PPROM before 22 weeks
  • Major fetal anomaly or congenital malformation
  • Mother refusal or inability to provide consent.
Both
up to 24 Hours
No
Contact: Olivier BAUD, Pr 01 40 03 41 09 olivier.baud@rdb.aphp.fr
France
 
NCT00623740
P 060250, 2007-002041-20
Yes
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Not Provided
Principal Investigator: olivier BAUD, Pr ASSISTANCE PULIQUE HOPITAUX DE PARIS
Assistance Publique - Hôpitaux de Paris
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP